Patents by Inventor Christian Lavedan

Christian Lavedan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLE MYELOMA TREATMENT
    Publication number: 20240342120
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: June 25, 2024
    Publication date: October 17, 2024
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • METHOD OF TREATMENT
    Publication number: 20240293355
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Application
    Filed: May 8, 2024
    Publication date: September 5, 2024
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • MULTIPLE MYELOMA TREATMENT
    Publication number: 20230346719
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: July 12, 2023
    Publication date: November 2, 2023
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Multiple myeloma treatment
    Patent number: 11737993
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 29, 2023
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • CANCER TREATMENT
    Publication number: 20230257471
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: April 25, 2023
    Publication date: August 17, 2023
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Cancer treatment
    Patent number: 11667718
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: June 6, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • TREATMENT OF CYR61- AND VEGF-MEDIATED CONDITIONS
    Publication number: 20220401464
    Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
    Type: Application
    Filed: August 25, 2022
    Publication date: December 22, 2022
    Inventors: Mihael H. POLYMEROPOULOS, Louis William LICAMELE, Christian LAVEDAN
  • Treatment of CYR61- and VEGF-mediated conditions
    Patent number: 11458154
    Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: October 4, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20220259660
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: April 8, 2022
    Publication date: August 18, 2022
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • METHOD OF TREATMENT
    Publication number: 20220133681
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Method of treatment
    Patent number: 11266622
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: March 8, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • CANCER TREATMENT
    Publication number: 20210324093
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: June 28, 2021
    Publication date: October 21, 2021
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Cancer treatment
    Patent number: 11078289
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 3, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
    Patent number: 11060144
    Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: July 13, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos, Gunther Birznieks
  • METHOD OF TREATMENT
    Publication number: 20200237712
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Method of treatment
    Patent number: 10653665
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10570453
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 25, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10570452
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 25, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10563261
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10563260
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele